Novartis on Tuesday said it was buying a U.S. biotech working on a cardiovascular drug, continuing what’s been a flurry of acquisitions at a similar price point.
Source link
Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range
You May Also Like
More From Author
‘Frenzied as ever’ — the Dan Ives-led Worldcoin treasury purchase is only latest example of market madness
